- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
- Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
- Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
- Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
- Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
More ▼
Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (ARWR:NSQ) closed at 25.40, 10.00% above the 52 week low of 23.09 set on Mar 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.59 |
---|---|
High | 25.56 |
Low | 24.43 |
Bid | 25.40 |
Offer | 25.49 |
Previous close | 24.43 |
Average volume | 1.09m |
---|---|
Shares outstanding | 108.31m |
Free float | 103.29m |
P/E (TTM) | -- |
Market cap | 2.75bn USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Mar 31 2023 21:00 BST.
More ▼